Omeprazole-d6

CAT:
804-HY-B0113S5
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Omeprazole-d6 - image 1

Omeprazole-d6

  • Description:

    Omeprazole-d6 (H 16868-d6) is deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) [3].
  • Product Name Alternative:

    H 16868-d6
  • UNSPSC:

    12352005
  • Target:

    Autophagy; Bacterial; Isotope-Labeled Compounds; Phospholipase; Proton Pump
  • Related Pathways:

    Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Cancer; Infection; Metabolic Disease
  • Smiles:

    CC(C(OC([2H])([2H])[2H])=C(C=N1)C)=C1CS(C(NC2=C3)=NC2=CC=C3OC([2H])([2H])[2H])=O
  • Molecular Formula:

    C17H13D6N3O3S
  • Molecular Weight:

    351.45
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[3]Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32 (8) :821-7.|[4]Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37 (1) :145-50.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Isotope-Labeled Compounds
  • Clinical Information:

    No Development Reported
  • CAS Number:

    [922731-02-0]